Clinical Trial: Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors

U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07656090) titled 'Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors' on Jan. 28.

Brief Summary: This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-Immune in patients with advanced solid tumors.

Study Start Date: Dec. 18, 2025

Study Type: INTERVENTIONAL

Condition: Cancer

Intervention: BIOLOGICAL: Oncolytic Virus injection(IDOV-Immune)

Administered by intravenous injection as single agent.

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Cancer Institute and Hospital, Chinese Acade...